Current guidelines endorse universal tumor testing for MMR deficiency in endometrial cancer, typically by MMR immunohistochemistry (IHC) with MSI testing (PCR or NGS) as an alternative or confirmatory approach [9]. This evidence concerns the gene MRC1 and endometrial cancer.